Tyrosine kinase inhibitorFDA-approvedFirst-line
Brafi
Generic name: vemurafenib
How it works
Blocks the activity of the BRAF V600E mutation in melanoma cells, preventing cancer growth.
Cancer types
Melanoma— BRAF V600E mutation-positive
Efficacy
In clinical trials, around 50% of patients with BRAF V600E mutation achieved an objective response, with median progression-free survival of approximately 6 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Melanoma Cells Resist Vemurafenib through Mitochondrial Changes | Melanoma | lab-study | — | Source → |
| New Compound May Help Fight Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Vemurafenib May Help Fight Melanoma by Triggering Cell Death | Melanoma | lab-study | — | Source → |
| Researchers Identify New Way to Overcome Resistance to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Researchers Create Melanoma Cell Lines Resistant to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Real-world study of melanoma treatment in Germany | Melanoma | observational | Median overall survival was 21.6 months in patients without brain metastases and 7.4 months in patients with brain metastases. | Source → |
| Cobimetinib Plus Vemurafenib Shows Antitumor Activity in Advanced Solid Tumors | Melanoma | phase-2 | The disease control rate was 68% and the objective response rate was 57%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.